Germany is the largest EU market and the natural European base for a US company — but it operates on a different logic. Employment, tax, data and (for life sciences) reimbursement all work in ways that surprise American teams. Here's what changes, and where the traps are.
For a US company, Germany is the EU gateway — but the operating model is different: no at-will employment, strong worker protections and works councils; a GmbH with a personally accountable managing director; combined corporate + trade tax around ~30% and 19% VAT; and GDPR, which is far stricter than the US patchwork. And if you're in healthcare, the biggest shift is pricing: in the US you largely set your price — in Germany it's assessed and negotiated. Germany rewards structure before visibility.
American companies enter Germany with a strong product and a proven playbook — and then meet a market that runs on different assumptions.
The instinct to “hire a country manager, sign a few deals, iterate fast” collides with German employment law, formality and planning norms. None of it is a barrier to success — German business is open to US companies — but the setup decisions carry more weight and are harder to reverse. Getting the structure right early is worth more here than moving fast and fixing later.
In the US you can improvise your way in. In Germany, the structure you choose on day one is the structure you live with.
The same six areas that feel routine at home behave differently in Germany. This is the shortlist most US entrants wish they'd seen first.
Most US companies operate through a German GmbH — a limited company with a minimum €25,000 share capital, notarised formation, and a managing director (Geschaeftsfuehrer) who carries real personal duties and liability, unlike a typical US officer.
The classic mistake is trying to avoid an entity: “we'll just have a US-employed salesperson cover Germany.” If that person can conclude contracts or operates from a fixed base, they can create a permanent establishment (Betriebsstaette) — a German taxable presence — before you meant to have one. The structure decision (and its tax consequences) should come first. We cover the options in our note on structuring an investment in Germany.
US companies routinely underestimate the GDPR. It's not a US-style sectoral rule but a strict, general regime with real enforcement — lawful basis, data-processing agreements, data-subject rights and breach reporting all apply.
Transatlantic data flows get particular scrutiny: after Schrems II, transfers to the US need a valid mechanism and documentation, and “we'll just run it on our US cloud” often doesn't survive review. For healthcare products the bar rises further — see our note on health-data security (GDPR & BSI).
For US pharma, medtech, biotech and digital-health companies, the largest shift isn't tax or employment — it's reimbursement. In the US you largely set your launch price and negotiate with payers and PBMs. In Germany, a marketing authorization or CE mark only lets you sell; what you're actually paid is assessed and negotiated through the public system.
Each track has its own mechanism — and none of them resembles the US model:
This is where a US launch plan most often breaks: the price ceiling is discovered after the cost base is built. In Germany, the reimbursement case belongs in the plan from day one — which is exactly the layer we own.
In a focused session we map the entity and tax setup, flag the employment and PE traps, and — if you're in life sciences — the reimbursement route that decides your revenue. Germany first; the EU from there.